Loading...
NRx Pharmaceuticals, Inc.
NRXPW•NASDAQ
Healthcare
Biotechnology
$0.07
$0.002(2.98%)

Over the last four quarters, NRx Pharmaceuticals, Inc. achieved steady financial progress, growing revenue from $8000.00 in Q4 2023 to $0.00 in Q3 2024. Gross profit stayed firm with margins at N/A in Q3 2024 versus 88% in Q4 2023. Operating income totaled -$3.02M in Q3 2024, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$1.62M. Net income rose to -$1.62M, with EPS at -$0.15. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan